A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Inclusion Criteria:

• Written informed consent

• At least 18 years of age

• Eastern Cooperative Oncology Group Performance Status score of 0 or 1

• Availability of archived tumor tissue samples

• Has a left ventricular ejection fraction (LVEF) ≥50% by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days before start of studytreatment

• Has adequate organ function within 7 days before the start of study treatment

• Has an adequate treatment washout period prior to start of study treatment

• Male participants with female partners of childbearing potential and femaleparticipants of child-bearing potential must agree to use a highly effective form ofcontraception or avoid intercourse during and upon completion of the study and forat least 4 months (for males) and for at least 7 months (for females) after the lastdose of study drug.

Exclusion Criteria:

• Has had prior treatment with other CDH6-targeted agents

• Has had prior treatment with an ADC that consists of an exatecan derivative that isa topoisomerase I inhibitor (e.g., trastuzumab deruxtecan, datopotamab deruxtecan,ifinatamab deruxtecan, DS-3939)

• Has history or current presence of CNS metastases except for participants who havecompleted radiotherapy or surgery ≥2 weeks before the start of study treatment andhave no evidence of disease progression in the CNS and no requirement for chroniccorticosteroid therapy within 2 weeks before the start of study treatment

• Has multiple primary malignancies, except adequately resected non-melanoma skincancer, curatively treated in situ disease, or other solid tumors curativelytreated, with no evidence of disease for ≥3 years)

• Has a history of myocardial infarction or unstable angina within 6 months beforestart of study treatment

• Has a medical history of symptomatic congestive heart failure (New York HeartAssociation classes II-IV) or a cardiac arrhythmia requiring treatment

• Lung-specific intercurrent clinically significant illnesses

• Has an uncontrolled infection requiring systemic therapy